Massive Bio Completes SOC 2 Type 1 Certification for Its AI Enabled Oncology Technology Platforms Including Patient Centric Clinical Trial Matching and Enrollment Services
NEW YORK–(BUSINESS WIRE)–#ChildhoodCancerAwareness—Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI) enabled…
Embedded LLM Launches the EU AI Grid at Munich Cyber Security Conference (MCSC) to Meet EU Demand for Sovereign AI Capability
Deveron Completes Transaction to Sell Its Assets